Leukocare Raises USD 17.5M in Financing
- Leukocare AG, USA-based biotechnology company specialized in the field of biopharmaceutical formulation development, closed a USD 17.5m financing
- The round was led by Petrichor Healthcare Capital Management, with participation from existing shareholders
- The financing consists of a USD 15m convertible loan and a USD 2.5m equity investment from Petrichor
- Proceeds will be used to accelerate company’s US expansion activities, bolster the company’s expertise in the fields of viral vector and vaccine formulation
- The company is a biotechnology company specialized in the field of biopharmaceutical formulation development
- In January 2021, The company started its US operations with the opening of development laboratories and offices in Milford, Massachusetts
